Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: A gynecologic oncology group study

Cancer

Volumn 98, Issue 8, 2003, Pages 1664-1669

  Scott Miller, David ^a   Blessing, John A ^b   Lentz, Samuel S ^c,e   Scott McMeekin, D ^d   Mackey, Denise ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e EAST CAROLINA UNIVERSITY   (United States)

^f Four Penn Center   (United States)

Author keywords

Chemotherapy; Gynecology; Medical oncology; Ovarian neoplasms; Topotecan

Indexed keywords

ALKALINE PHOSPHATASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLATINUM; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; TOPOTECAN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LEUKOPENIA; LUNG TOXICITY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR RECURRENCE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 0141923865     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11690     Document Type: Article

References (20)

1. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. J Clin Oncol. 1996;14:3056-3061.
2. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552-1557.
3. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345-3352.
4. Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16: 2233-2237.
5. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:1062-1067.
6. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193.
7. Armstrong D, O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist. 1998;3: 4-10.
8. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol. 2000;79:116-119.
9. Brown JV III, Peters WA III, Rettenmaier MA, et al. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol. 2000;79:495-498.
10. Homesley HD, Hall DJ, Martin DA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 2001;83:394-399.
11. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol. 2001;83:257-262.
12. Markman M, Blessing JA, De Geest K, et al. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial. Gynecol Oncol. 1999;75:444-446.
13. Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;77:112-115.
14. ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin Oncol. 1997;24 (1 Suppl 5):S5-19-S5-25.
15. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res. 1972;32:2643-2650.
16. Rowinsky EK, Verwelj J. Review of phase I clinical studies with topotecan. Semin Oncol. 1997;24:S20-3-S20-10.
17. Hochster H, Wadler S, Runowicz C, et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 1999;17:2553-2561.
18. Johnson S, Pyle L, King K, Gore M. A phase II study of topotecan given as a continuous 21-day infusion every 28 days in platinum pre-treated ovarian carcinoma [abstract]. Eur J Cancer. 1997;33 (Suppl 8):S120.
19. O'Reilly S, Fleming GF, Barker SD, et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15: 177-186.
20. Gordon AN, Doherty M, Hancock KC, et al. Phase I study of topotecan (T) with carboplatin (C) alternating with paclitaxel (P) via 3 hour infusion in combination with carboplatin (C) in treatment of newly diagnosed ovarian cancer (OC) patients [abstract]. Proc Am Soc Clin Oncol. 1999;18:364A.